Zara Baloch, Director of Quantitative Research and Meta Analysis, Digital Education Manager and Host at MedNews Week, shared on LinkedIn:
”CAR-T is changing what’s possible but who gets to benefit?
After transforming treatment for certain blood cancers, CAR-T is now being explored in solid tumors, rheumatology, and immune-mediated diseases.
CAR-T is a personalized immunotherapy that reprograms a patient’s own T cells to recognize and target specific abnormal cells.
At the National ICE-T Congress in Orlando, experts shared where CAR-T stands today, where the field is heading, and the barriers that continue to shape patient access.
The science is moving quickly. Access and equity must move with it.”
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on LinkedIn by Zara Baloch, adding:
“Thank you to Dr. Zara Baloch for taking the time to cover this important topic of the present and future of CAR T cell therapy as our MedNews Week medical correspondent at the 2026 ICE-T Conference.”
Other posts featuring Yan Leyfman on OncoDaily.